2017 Astellas Transparency Disclosure Report
Astellas is a member company of the European Federation of Pharmaceutical Industries and Associations (“EFPIA”) and adheres to the EFPIA Disclosure Code 2014 (the “EFPIA Disclosure Code”).
The EFPIA Disclosure Code requires all member companies to document and disclose certain Transfers of Value they make, directly or indirectly, to or for the benefit of, Healthcare Professionals (“HCPs”) or Healthcare Organisations (“HCOs”) (“Disclosures”).
The EFPIA Disclosure Code is implemented in Finland by the Pharma Industry Finland’s (PIF) Code of Ethics. Astellas discloses all Transfers of Value to HCPs and HCOs in accordance with its commitment to the EFPIA Disclosure Code and any applicable Finnish national code.
Astellas’ global vision is to be in the forefront of healthcare change by turning innovative science into value for patients.
Most of Astellas Finland’s financial support was focusing on education for Healthcare Organisations and Healthcare Professionals in Nephrology, Oncology and Urology specialty areas during 2017.
The costs were mostly due to the travel and accommodation 23% of the total costs (165 167.45 €). And also some honorarium for some lectures 9.4% of the total costs (66 843.10 €). Astellas’ financial support for R&D in Finland was 350 323.01 €.
Astellas Finland provided support for congress education internationally.
Astellas Finland supported locally Nephrology, Oncology and Urology Associations to organize education events. And also hospitals to organize local educational events.